接受酶替代治疗的CLN2-Batten病患者的运动障碍演变
该研究在单中心对18例接受cerliponase alfa酶替代治疗(ERT)的CLN2-Batten病儿童进行系统评估,采用标准化病史和双评分视频记录的UBDRS及异常不自主运动量表。结果显示运动障碍常见且进展模式刻板,ERT可减缓运动障碍进展,UBDRS躯体亚量表在诊断前每月进展1.45分,治疗期间每月进展0.44分(p=0.019)。
要点
- CLN2-Batten病运动障碍常见:共济失调89%、肌阵挛83%,痉挛和肌张力障碍各61%。
- 患儿中位有4种不同的运动障碍表型,进展模式刻板:先共济失调/肌阵挛,继而多动/痉挛,后期运动减少。
- ERT减缓运动障碍进展,UBDRS躯体亚量表进展速度从诊断前每月1.45分降至治疗期间每月0.44分(p=0.019)。
核心结论
- 运动障碍是CLN2-Batten病的核心特征,并遵循典型的进展模式,ERT可减缓该进展。
- 作者认为,识别和治疗运动障碍应成为标准做法,尤其考虑到患者生存率提高。
研究设计与样本
- 单中心队列研究,纳入18例接受cerliponase alfa酶替代治疗的CLN2-Batten病儿童。
- 采用标准化结构化病史和双评分视频记录的检查,使用统一Batten病评定量表(UBDRS)和异常不自主运动量表进行评估。
主要发现
- 共济失调(89%)和肌阵挛(83%)接近普遍,痉挛和肌张力障碍各占61%,患儿中位有4种不同的运动障碍表型。
- 运动障碍进展模式刻板:初始为共济失调/肌阵挛,然后为多动/痉挛,后期为运动减少。
- UBDRS躯体亚量表进展速度:诊断前每月1.45分,治疗期间每月0.44分(p=0.019)。
临床怎么用
- 作者认为,识别和治疗运动障碍应成为标准做法,尤其考虑到患者生存率提高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Neuronal ceroid lipofuscinosis type 2 (CLN2-disease) is an inherited childhood-onset neurodegenerative condition, with classical early features of speech delay, epilepsy, myoclonus, ataxia, and motor regression. This study aimed to better characterize the spectrum of movement disorders in CLN2-disease in a cohort of children receiving enzyme replacement therapy (ERT). METHODS: A cohort of 18 children attending a single center for treatment with cerliponase alfa ERT was systematically assessed using a standardized structured history and a double-scored, video-recorded examination using the Unified Batten Disease Rating Scale (UBDRS) and Abnormal Involuntary Movement Scale. RESULTS: Noncanonical movement disorders are common: while ataxia (89%) and myoclonus (83%) were near-universal, spasticity and dystonia were experienced by over half (61% each), with children having a median of 4 distinct movement disorder phenotypes. This progression was stereotyped with initial ataxia/myoclonus, then hyperkinesia/spasticity, and later hypokinesia. ERT slows progression of movement disorders, as measured by the UBDRS physical subscale, with 1.45 points-per-month progression before diagnosis and 0.44 points-per-month while on treatment (p = 0.019). DISCUSSION: Movement disorders are a core feature of CLN2-disease and follow a typical pattern of progression which is slowed by ERT. Identifying and treating movement disorders should become standard, especially given increased patient survival.
引用
- Spaull R, Soo AK, Batzios S, et al. Evolution of Movement Disorders in Patients With CLN2-Batten Disease Treated With Enzyme Replacement Therapy. Neurology. 2024. PMID: 38976822. doi:10.1212/WNL.0000000000209615
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。